NASDAQ:DRIO DarioHealth Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DarioHealth Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.95 +1.54 (+8.85 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$17.13Now: $18.95▼$18.9950-Day Range$8.07MA: $16.07▼$20.2052-Week Range$3.02Now: $18.95▼$22.49Volume162,187 shsAverage Volume135,864 shsMarket Capitalization$159.56 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.33, DarioHealth has a forecasted downside of 8.5% from its current price of $18.95.Amount of Analyst CoverageDarioHealth has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesDarioHealth has received 222 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDarioHealth has received 209 “underperform” votes. (Add your “underperform” vote.)Community SentimentDarioHealth has received 51.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DarioHealth and other stocks. Vote “Outperform” if you believe DRIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 21.20% of the stock of DarioHealth is held by insiders.Percentage Held by InstitutionsOnly 5.59% of the stock of DarioHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DarioHealth are expected to grow in the coming year, from ($4.93) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DarioHealth is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DarioHealth is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRIO Previous Symbol CUSIPN/A CIKN/A Webwww.mydario.com Phone972-4770-4055Debt Debt-to-Equity Ratio0.03 Current Ratio3.39 Quick Ratio3.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.56 million Price / Sales21.11 Cash FlowN/A Price / Cash FlowN/A Book Value$8.45 per share Price / Book2.24Profitability EPS (Most Recent Fiscal Year)($8.00) Net Income$-17,740,000.00 Net Margins-293.20% Return on Equity-165.09% Return on Assets-118.29%Miscellaneous Employees69 Outstanding Shares8,420,000Market Cap$159.56 million Next Earnings Date10/26/2020 (Estimated) OptionableNot Optionable $18.95 +1.54 (+8.85 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DRIO News and Ratings via Email Sign-up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter. DarioHealth (NASDAQ:DRIO) Frequently Asked Questions How has DarioHealth's stock price been impacted by Coronavirus (COVID-19)? DarioHealth's stock was trading at $6.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRIO stock has increased by 175.0% and is now trading at $18.95. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of DarioHealth? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DarioHealth. When is DarioHealth's next earnings date? DarioHealth is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020. View our earnings forecast for DarioHealth. How were DarioHealth's earnings last quarter? DarioHealth Corp (NASDAQ:DRIO) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.86. The company had revenue of $1.79 million for the quarter, compared to the consensus estimate of $1.72 million. DarioHealth had a negative return on equity of 165.09% and a negative net margin of 293.20%. View DarioHealth's earnings history. What price target have analysts set for DRIO? 3 Wall Street analysts have issued 1-year target prices for DarioHealth's stock. Their forecasts range from $10.00 to $25.00. On average, they expect DarioHealth's stock price to reach $17.33 in the next year. This suggests that the stock has a possible downside of 8.5%. View analysts' price targets for DarioHealth. Are investors shorting DarioHealth? DarioHealth saw a increase in short interest in August. As of August 31st, there was short interest totaling 162,200 shares, an increase of 109.3% from the August 15th total of 77,500 shares. Based on an average daily trading volume, of 261,600 shares, the short-interest ratio is presently 0.6 days. Approximately 3.2% of the shares of the stock are short sold. View DarioHealth's Short Interest. Who are some of DarioHealth's key competitors? Some companies that are related to DarioHealth include Invo Bioscience (IVOB), Tactile Systems Technology (TCMD), AVITA MED LTD/S (RCEL), Orthofix Medical (OFIX), Intersect ENT (XENT), SurModics (SRDX), Anika Therapeutics (ANIK), Antares Pharma (ATRS), Co-Diagnostics (CODX), Alphatec (ATEC), SeaSpine (SPNE), AngioDynamics (ANGO), Cytosorbents (CTSO), Repro Med Systems (KRMD) and Pulse Biosciences (PLSE). View all competitors. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include AEterna Zentaris (AEZS), Vascular Biogenics (VBLT), NANO DIMENSION/S (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL). Who are DarioHealth's key executives? DarioHealth's management team includes the following people: Mr. Erez Raphael, CEO & Director (Age 46)Mr. Olivier R. Jarry, Pres & Chief Commercial Officer (Age 58)Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 58)Mr. Dror Bacher, Chief Operating Officer (Age 44)Ms. Joao Mendes-Roter, VP of Marketing What is DarioHealth's stock symbol? DarioHealth trades on the NASDAQ under the ticker symbol "DRIO." Who are DarioHealth's major shareholders? DarioHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Meitav Dash Investments Ltd. (2.27%) and Goldman Sachs Group Inc. (0.72%). Company insiders that own DarioHealth stock include Adam K Stern, Allen Kamer, Erez Raphael, Hila Karah and Yoav Shaked. View institutional ownership trends for DarioHealth. Which major investors are buying DarioHealth stock? DRIO stock was acquired by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., and Goldman Sachs Group Inc.. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, Allen Kamer, Erez Raphael, Hila Karah, and Yoav Shaked. View insider buying and selling activity for DarioHealth. How do I buy shares of DarioHealth? Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DarioHealth's stock price today? One share of DRIO stock can currently be purchased for approximately $18.95. How big of a company is DarioHealth? DarioHealth has a market capitalization of $159.56 million and generates $7.56 million in revenue each year. The company earns $-17,740,000.00 in net income (profit) each year or ($8.00) on an earnings per share basis. DarioHealth employs 69 workers across the globe. What is DarioHealth's official website? The official website for DarioHealth is www.mydario.com. How can I contact DarioHealth? DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
